Cardiovascular disease and the UN Millennium Development Goals: a serious concern

Valentin Fuster

doi:10.1038/ncpcardio0630 | Full Text | PDF (74K)

Vascular access site complications after PCI: current status and future directions

Martial Hamon

Major bleeding is the most common noncardiac complication after percutaneous coronary intervention for coronary artery disease. The reduction of vascular access site complications in PCI procedures is, therefore, a critical challenge. In this month's Viewpoint, Martial Hamon discusses why an alternative access site is needed and compares the benefits of the transradial approach with those of the femoral approach.

doi:10.1038/ncpcardio0607 | Full Text | PDF (96K)

The metabolic syndrome predicts cardiovascular prognosis

doi:10.1038/ncpcardio0587 | Full Text | PDF (100K)

Candesartan is effective in treating prehypertension

doi:10.1038/ncpcardio0588 | Full Text | PDF (88K)

Imaging by 64-slice CT accurately diagnoses stenosis in CABG

doi:10.1038/ncpcardio0589 | Full Text | PDF (97K)

C-reactive protein levels are increased in active carotid artery plaques

doi:10.1038/ncpcardio0590 | Full Text | PDF (100K)

Atrioesophageal fistula: a potentially fatal complication of radiofrequency ablation

doi:10.1038/ncpcardio0591 | Full Text | PDF (96K)

Reduced neurohormone activation in patients with HF after aerobic physical training

doi:10.1038/ncpcardio0592 | Full Text | PDF (99K)

Treatment of aortic hypoplasia by stent expansion

doi:10.1038/ncpcardio0593 | Full Text | PDF (87K)

Microvolt T-wave alternans predicts mortality in patients with ischemic cardiomyopathy

doi:10.1038/ncpcardio0594 | Full Text | PDF (96K)

Sirolimus-eluting stents exhibit incomplete neointimal coverage

doi:10.1038/ncpcardio0595 | Full Text | PDF (99K)

Risk of cardiovascular disease very high in patients with type 1 diabetes

doi:10.1038/ncpcardio0596 | Full Text | PDF (97K)

Septal morphology is related to genotype in hypertrophic cardiomyopathy

doi:10.1038/ncpcardio0608 | Full Text | PDF (100K)

Ethnic differences in risk of MI among patients with ESRD

doi:10.1038/ncpneph0214 | Full Text | PDF (88K)

Growth hormone therapy has a positive effect on cardiovascular risk

doi:10.1038/ncpendmet0210 | Full Text | PDF (86K)

Combining prestroke treatments reduces stroke severity

doi:10.1038/ncpneuro0235 | Full Text | PDF (87K)

Can tailored ablation procedures successfully eliminate recurrent atrial fibrillation?

John M Miller and Girish V Nair

doi:10.1038/ncpcardio0627 | Full Text | PDF (97K)

Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy?

Vittorio Pengo

doi:10.1038/ncpcardio0612 | Full Text | PDF (97K)

HOPE 2: can supplementation with folic acid and B vitamins reduce cardiovascular risk?

Iftikhar J Kullo

doi:10.1038/ncpcardio0611 | Full Text | PDF (101K)

Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?

Karen E Thomas and Duane S Pinto

doi:10.1038/ncpcardio0628 | Full Text | PDF (98K)

Can brain natriuretic peptide be used to diagnose and manage patients with diastolic heart failure?

Burkert Pieske

doi:10.1038/ncpcardio0606 | Full Text | PDF (101K)

ASSENT-4 PCI: should facilitated percutaneous coronary intervention be used in clinical practice?

Kanwar P Singh and Matthew T Roe

doi:10.1038/ncpcardio0626 | Full Text | PDF (101K)

Should prophylactic amiodarone therapy be used to prevent atrial tachyarrhythmia after cardiac surgery?

Atul Verma, Subodh Verma, Lee Errett and Paul Dorian

doi:10.1038/ncpcardio0629 | Full Text | PDF (102K)

Update on lipid-lowering therapy and LDL-cholesterol targets

Stephen D Wiviott and Christopher P Cannon

Despite LDL-cholesterol targets being lowered several times in recent years, are they low enough? New data continue to be published showing that LDL lowering should be a primary target of therapy, with the possibility of simultaneously raising HDL cholesterol. Wiviott and Cannon bring together the extensive data to provide an update.

doi:10.1038/ncpcardio0613 | Full Text | PDF (246K)

Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease

Mark E Anderson, Linda S Higgins and Howard Schulman

Many protein kinases are positioned proximal to critical proteins that mediate cell function. Since these functions can be altered by disease, attention has turned to protein kinases as therapeutic targets. In this Review, the role of protein kinases in myocardial disease, and the pharmacologic therapy possibilities they present are discussed.

doi:10.1038/ncpcardio0585 | Full Text | PDF (260K)